Hospital
Columbia Medical Center of Arlington Subsidiary LP
Columbia Medical Center of Arlington Subsidiary LP was paid $21.83M by Medicaid between Jan 2020 and Dec 2024, across 78 billing codes. Its largest line is 99283, emergency room visit (moderate) — 48% of everything it billed.
33Billing provider infoCOLUMBIA MEDICAL CENTER OF ARLINGTON SUBSIDIARY LP
ARLINGTON, TX 76015
ARLINGTON, TX 76015
33aNPI1134172406assigned 05/18/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$21.83M
24GClaims308,317
24DCodes billed78
24AFirst – last monthJan 2020 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Texas
Rank by total paid#4 of 109
Median peer was paid$1.15M
This provider vs. median19×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 15,448 | $532K | |
| 2021 | 71,726 | $4.19M | |
| 2022 | 91,644 | $6.19M | |
| 2023 | 84,668 | $7.24M | |
| 2024incomplete | 44,831 | $3.67M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 48% | 61,866 | 60,339 | $10.54M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 36% | 22,785 | 21,102 | $7.96M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.6% | 3,656 | 3,593 | $557K |
| 71045 | Radiologic examination, chest; single view | 1.9% | 23,710 | 22,760 | $410K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.3% | 6,695 | 6,547 | $274K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.2% | 6,077 | 5,559 | $253K |
| 87430 | 1.0% | 18,755 | 18,430 | $222K | |
| 80053 | Comprehensive metabolic panel | 1.0% | 13,652 | 12,586 | $220K |
| 87275 | <1% | 19,162 | 18,785 | $206K | |
| 87276 | <1% | 19,161 | 18,783 | $204K | |
| 87070 | <1% | 13,980 | 13,719 | $151K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,934 | 2,369 | $78K |
66 more codes
| 99285 | Emergency room visit (most serious) | <1% | 1,069 | $75K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,173 | $74K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 428 | $70K |
| 85027 | <1% | 22,374 | $66K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 849 | $65K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 6,620 | $55K |
| 81025 | <1% | 9,828 | $52K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,404 | $50K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,573 | $35K |
| 81001 | <1% | 9,225 | $24K | |
| 84484 | <1% | 4,285 | $22K | |
| 87280 | <1% | 1,693 | $18K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,575 | $15K |
| 84702 | <1% | 1,135 | $14K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,664 | $14K |
| 83690 | <1% | 4,584 | $12K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,998 | $12K |
| 76830 | Ultrasound, transvaginal | <1% | 117 | $11K |
| 81003 | <1% | 1,068 | $10K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 900 | $10K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 85 | $8K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,600 | $6K |
| 76801 | <1% | 44 | $5K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 259 | $4K |
| 83880 | <1% | 1,252 | $4K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,090 | $4K |
| 81000 | <1% | 595 | $4K | |
| 80047 | <1% | 57 | $2K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 691 | $2K |
| 86901 | <1% | 899 | $2K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 14 | $982.32 |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 13 | $962.80 |
| 71046 | Radiologic examination, chest; 2 views | <1% | 135 | $958.50 |
| 85730 | <1% | 1,078 | $929.27 | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 26 | $901.79 |
| 85610 | <1% | 1,365 | $854.12 | |
| A9270 | Non-covered item or service | <1% | 1,961 | $847.39 |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 69 | $730.80 |
| 82016 | <1% | 87 | $574.56 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 968 | $543.77 |
| 82128 | <1% | 87 | $519.85 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 48 | $508.19 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 975 | $469.86 |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 48 | $457.44 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 381 | $422.46 |
| 86850 | <1% | 40 | $383.54 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 410 | $317.13 |
| 74018 | <1% | 14 | $283.14 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 14 | $256.71 |
| 86900 | <1% | 152 | $208.90 | |
| 81002 | <1% | 65 | $160.27 | |
| 87081 | <1% | 56 | $136.60 | |
| 83735 | <1% | 214 | $118.85 | |
| 36416 | <1% | 872 | $111.88 | |
| 87077 | <1% | 37 | $74.69 | |
| 87186 | <1% | 30 | $65.43 | |
| 87040 | <1% | 19 | $43.35 | |
| 83605 | <1% | 49 | $38.88 | |
| 84703 | <1% | 12 | $37.92 | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 37 | $19.17 |
| 82248 | <1% | 75 | $14.75 | |
| J3490 | Unclassified drugs | <1% | 14 | $13.28 |
| 80076 | <1% | 64 | $12.92 | |
| 84100 | <1% | 32 | $4.36 | |
| G1003 | Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program | 0% | 202 | $0.00 |
| S3620 | Newborn metabolic screening panel, includes test kit, postage and the laboratory tests specified by the state for inclusion in this panel (e.g., galactose; hemoglobin, electrophoresis; hydroxyprogesterone, 17-d; phenylalanine (pku); and thyroxine, total) | 0% | 87 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTINDALL, NATHAN (CFO)